Vimarsana
Biggest News Aggregation in the World

Page 2 - Dawood Sayed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dawood Sayed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dawood Sayed Today - Breaking & Trending Today

Landmark Prospective Evidence on Posterior Approach to SI Joint Fusion Reflects Improved Pain Scores at 6 & 12 Months - Vimarsana News

Landmark Prospective Evidence on Posterior Approach to SI Joint Fusion Reflects Improved Pain Scores at 6 & 12 Months

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Landmark Prospective Evidence on Posterior Approach to SI Joint Fusion Reflects Improved Pain Scores at 6 & 12 Months - Vimarsana News

Landmark Prospective Evidence on Posterior Approach to SI Joint Fusion Reflects Improved Pain Scores at 6 & 12 Months

TAMPA, Fla., Jan. 25, 2022 /PRNewswire/ -- Preliminary data from the landmark SI joint fusion study of Tampa-based medical device company, PainTEQ...

Stratus™ Medical strengthens global patent portfolio with three new patents issued for the Nimbus® RF Multitined Expandable Electrode used to treat pain - Vimarsana News

Stratus™ Medical strengthens global patent portfolio with three new patents issued for the Nimbus® RF Multitined Expandable Electrode used to treat pain

/PRNewswire/ -- Stratus™ Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced three new patents today....

Real-World Review of PainTEQ's Minimally Invasive SI Joint Fusion Device Reports Long-Term Efficacy and Safety - Vimarsana News

Real-World Review of PainTEQ's Minimally Invasive SI Joint Fusion Device Reports Long-Term Efficacy and Safety

/PRNewswire/ -- A new multicenter real-world study of PainTEQ's LinQ device reflected long-term success and safety in treating sacroiliac (SI) joint...

First Patient Treated in Landmark U.S. Randomized Clinical Trial of NeuraLace's Chronic Pain Treatment - Vimarsana News

First Patient Treated in Landmark U.S. Randomized Clinical Trial of NeuraLace's Chronic Pain Treatment

Share this article Share this article SAN DIEGO, May 27, 2021 /PRNewswire/ -- NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic nerve pain, announced today that the first patient has been enrolled as part of the AXON-RCT U.S. study: a prospective, randomized, controlled clinical trial comparing the safety and effectiveness of Axon Therapy® for post-traumatic peripheral neuropathic pain to conventional medical management.  The Primary Investigator of the study will be Dr. Leonardo Kapural of the Carolinas Pa...